In Massachusetts, Lilly Asia Ventures, Trustbridge Partners, and Jiangsu Simcere Pharmaceutical gave Veritas Genetics $30 million in Series B funding. Veritas Genetics focuses on genome sequencing and genetic screening tests, mostly related to cancer and reproductive health. Veritas was the first company to offer genetic sequencing for under $1,000, making it a realistic prospect for more people. Mirza Cifric, founder and CEO of Veritas Genetics, told PR Newswire, “With a $999 genome, we are at the tipping point of a transformation in healthcare where the genome is going to be at the center of many decisions we make about our health and quality of life, throughout our lives.” This latest funding will go towards global expansion of operations and hospital and researcher partnerships. They welcomed three new executives to their team to help with the expansion, Tim Smith as Chief Operating Officer, Rodrigo Martinez as Chief Marketing and Design Officer, and Doug Flood as Chief Commercial Officer.
Latest article
Mercedes-Benz taps Modern Meadow for 80% plant-based leather
In Germany, luxury car manufacturer Mercedes-Benz has partnered with New Jersey biodesign firm Moden Meadow to develop a next-generation leather alternative for its CONCEPT...
Bioluminescent dress from van Herpen portends era of living couture
In France, Dutch fashion designer Iris van Herpen has unveiled a dress embedded with 125 million bioluminescent algae at Paris Haute Couture Week 2025....
Stella McCartney’s latest sneaker can be composted, smells of cinnamon
In London, sustainable fashion pioneer Stella McCartney has unveiled a new version of its S-Wave sneakers, featuring soles made entirely from BioCir Flex, a...